Preliminary Experiences with Isoprodian(R) in the Treatment of Pulmonary Tuberculosis
The WHO Committee on Tuberculosis emphasized in its last report (1974) the importance to secure adequate chemotherapy to every patient with infectious pulmonary tuberculosis. Such treatment should combine effectivity and acceptable toxicity, should be convenient both to dispense and for the patient to take and, last but not least, its cost should also be “adequate”, which certainly does not apply only to so called developing countries.
KeywordsSerum Uric Acid Pulmonary Tuberculosis Total Patient Serum Urea Nitrogen British Medical Research Council
Unable to display preview. Download preview PDF.
- Blaha H. and Rottach H. (1974), Praxis der Pneumologie 28,930Google Scholar
- British Medical Research Council Co-operative Study (1973), Tubercle, 54, 99Google Scholar
- East African/British Medical Research Council Sulphone Investigation (1959), Tubercle 40, 1Google Scholar
- Fox, W. and Mitchison, D.A. (1975), American Review of Respiratory Diseases, 111, 325Google Scholar
- Freerksen, E. (1973), Lecture presented during the 13th Meeting of the North German Association for Tuberculosis and Respiratory Diseases, Celle, Germany, October 19–21Google Scholar
- Lees, A.W., (1965), 18th Conference of the International Union Against Tuberculosis, Munich, Excerpta Medica, International Congress Series No. 96, 112Google Scholar
- WHO Expert Committee on Tuberculosis (1974), 9th Report, World Health Organization Technical Report Series No. 552, 17Google Scholar